Molecular profiling in muscle‐invasive bladder cancer: more than the sum of its parts

• Published in: The Journal of pathology Vol. 247; no. 5; pp. 563 - 573
• Main Authors: Sjödahl, Gottfrid, Jackson, Chelsea L, Bartlett, John MS, Siemens, D Robert, Berman, David M
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.04.2019; Wiley Subscription Services, Inc
• Subjects: Biomarkers, Tumor - metabolism; Bladder cancer; bladder neoplasms; Breast cancer; Cancer and Oncology; Cancer och onkologi; cancer stem cell; Chemotherapy; Clinical Medicine; Cytostatic Agents - therapeutic use; Cytotoxicity; Epidermal growth factor receptors; ErbB-2 protein; Fibroblast growth factor receptors; GATA3; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic; Growth factors; Heterogeneity; Humans; Immune checkpoint; Immunohistochemistry; Invasiveness; Klinisk medicin; KRT5; LUNDTAX; Medical and Health Sciences; Medicin och hälsovetenskap; Muscle Neoplasms - genetics; Muscle Neoplasms - pathology; Muscles; Mutation - genetics; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins - genetics; PD-1 protein; PPARG; Prognosis; RB1; Shh; TGFB; Therapeutic applications; TP53; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - pathology; Urologi och njurmedicin; Urology and Nephrology; Workflow; RB1; bladder neoplasms; Shh; cancer stem cell; TGFB; PPARG; GATA3; KRT5; LUNDTAX; TP53

Bladder cancers are biologically and clinically heterogeneous. Recent large‐scale transcriptomic profiling studies focusing on life‐threatening muscle‐invasive cases have demonstrated a small number of molecularly distinct clusters that largely explain their heterogeneity. Similar to breast cancer,...